Background
Ovarian cancer is a heterogenous malignancy with multiple histological
subtypes. The most common form of ovarian cancer is epithelial ovarian
cancer, of which the serous subtype is most common. The second most
common, accounting for approximately 10% of epithelial ovarian cancers,
is endometrioid carcinoma [1]. As a result of the rare nature of
ovarian endometrioid carcinoma, research and understanding of this
subtype, its presentation, management, and prognosis, are limited.
Cytoreductive surgery remains the mainstay treatment for this subtype of
ovarian cancer, and the extent of tumour resection has been suggested to
be a major prognostic factor [2-4].
Here we present the case of a woman in her late 40’s with pelvic
recurrence of endometrioid ovarian cancer. The patient has consented for
this case report to be written and published. The initial histopathology
report graded the tumour as grade 1, without any evidence of clear
cells, an indicator of aggressiveness. The cancer was
International Federation of
Gynecology and Obstetrics (FIGO) stage IC2, restricted to the ovaries
and on a background of atypical endometriosis. This case highlights the
surgical complexity of optimal cytoreductive surgery in recurrent
endometrioid ovarian cancer, best achieved by a multidisciplinary
approach.